|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1718192021222324252627...4041» |
- | dalfampridine / Generic mfg.
New P2 trial: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jun 19, 2014
P2, N=25, Recruiting, Sponsor: Johns Hopkins University
- ||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Enrollment closed: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jun 19, 2014
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: A P300 Brain Computer Interface to Operate Power Wheelchair Tilt (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=16, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=48 --> 16
- Trial primary completion date: Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=50, Completed, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed | N=48 --> 16 Trial primary completion date: Dec 2012 --> Sep 2011
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, IO biomarker, Metastases: Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma (clinicaltrials.gov) - Jun 19, 2014
P2, N=50, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2012 --> Sep 2011 Trial primary completion date: May 2014 --> May 2016
- Enrollment change: Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=50, Completed, Sponsor: University Hospital, Rouen
Trial primary completion date: May 2014 --> May 2016 N=40 --> 50
- New P1/2 trial: Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=20, Recruiting, Sponsor: Yale University
- Trial completion, Enrollment change, Trial primary completion date: Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=50, Completed, Sponsor: University Hospital, Rouen
N=40 --> 50 Recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2012 --> Sep 2011
- | fipaxalparant (AMG 670) / Amgen
Trial completion: Proof of Biological Activity of SAR100842 in Systemic Sclerosis (clinicaltrials.gov) - Jun 18, 2014
P2, N=30, Completed, Sponsor: Sanofi
Recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2012 --> Sep 2011 Active, not recruiting --> Completed
- | deferiprone / Generic mfg.
New P2 trial: SAFEFAIRALS: Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (clinicaltrials.gov) - Jun 17, 2014
P2, N=18, Recruiting, Sponsor: University Hospital, Lille
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=6503, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed N=2000 --> 6503
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: TYGRIS: TYSABRI Global Observational Program in Safety (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=2207, Active, not recruiting, Sponsor: Biogen Idec
N=2000 --> 6503 N=3000 --> 2207
- pyrimethamine / Generic mfg.
Enrollment closed: SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jun 13, 2014
P1/2, N=40, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
N=3000 --> 2207 Recruiting --> Active, not recruiting
- ||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 13, 2014
P2/3, N=106, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change: Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - Jun 13, 2014
P1, N=55, Completed, Sponsor: Biogen Idec
Recruiting --> Completed N=30 --> 55
- Avastin (bevacizumab) / Roche
Phase classification: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jun 12, 2014
P1, N=10, Recruiting, Sponsor: Johns Hopkins University
N=30 --> 55 Phase classification: P2 --> P1
- Trial primary completion date: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=123, Completed, Sponsor: University of Washington
Phase classification: P2 --> P1 Trial primary completion date: Sep 2014 --> Dec 2012
- Enrollment open: Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=10, Recruiting, Sponsor: University of Manitoba
Trial primary completion date: Sep 2014 --> Dec 2012 Not yet recruiting --> Recruiting
- Trial completion: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=123, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial withdrawal: PRISS: Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis (clinicaltrials.gov) - Jun 5, 2014
P4, N=0, Withdrawn, Sponsor: University of Michigan
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: PRISS: Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis (clinicaltrials.gov) - Jun 5, 2014
P4, N=0, Withdrawn, Sponsor: University of Michigan
Not yet recruiting --> Withdrawn N=32 --> 0
- ||| Enrollment closed: Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) - Jun 3, 2014
P4, N=151, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=32 --> 0 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 3, 2014
P3, N=162, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Active, not recruiting --> Completed Trial primary completion date: Feb 2014 --> Sep 2014
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Trial primary completion date: Feb 2014 --> Sep 2014 N=18 --> 48
- | Trial initiation date, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Jun 3, 2014
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 48 Initiation date: Jul 2012 --> Oct 2012
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) - Jun 2, 2014
P4, N=90, Recruiting, Sponsor: EMD Serono
Initiation date: Jul 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases (clinicaltrials.gov) - Jun 2, 2014
P1, N=20, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Jan 2018
- teriflunomide / Generic mfg.
Enrollment open: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jun 2, 2014
P1, N=12, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jan 2015 --> Jan 2018 Not yet recruiting --> Recruiting
- Trial completion: Optical Coherence Tomography in Multiple Sclerosis Patients (clinicaltrials.gov) - May 29, 2014
P=N/A, N=78, Completed, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Completed
- || rHIgM22 / Acorda
Trial primary completion date: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 29, 2014
P1, N=71, Active, not recruiting, Sponsor: Acorda Therapeutics
Recruiting --> Completed Trial primary completion date: Jul 2014 --> Nov 2014
- || rHIgM22 / Acorda
Enrollment closed: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 29, 2014
P1, N=71, Active, not recruiting, Sponsor: Acorda Therapeutics
Trial primary completion date: Jul 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- || Enrollment change: JEMS: JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (clinicaltrials.gov) - May 28, 2014
P=N/A, N=7726, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting N=2000 --> 7726
- | Myrbetriq (mirabegron) / Astellas
Trial initiation date: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - May 27, 2014
P2/3, N=72, Enrolling by invitation, Sponsor: Lawson Health Research Institute
N=2000 --> 7726 Initiation date: Apr 2014 --> Jul 2014
- | Myrbetriq (mirabegron) / Astellas
Enrollment open: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - May 27, 2014
P2/3, N=72, Enrolling by invitation, Sponsor: Lawson Health Research Institute
Initiation date: Apr 2014 --> Jul 2014 Not yet recruiting --> Enrolling by invitation
- | dalfampridine / Generic mfg.
New P4 trial: Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (clinicaltrials.gov) - May 22, 2014
P4, N=50, Recruiting, Sponsor: Clinique Neuro-Outaouais
- || GSK239512 / GSK
Trial primary completion date: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - May 21, 2014
P2, N=114, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Oct 2014 --> Sep 2014
- || GSK239512 / GSK
Trial completion date: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - May 21, 2014
P2, N=114, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2014 --> Sep 2014 Trial completion date: Oct 2014 --> Sep 2014
- || ZB-168 / Zura Bio
Trial primary completion date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 21, 2014
P1, N=60, Not yet recruiting, Sponsor: Pfizer
Trial completion date: Oct 2014 --> Sep 2014 Trial primary completion date: May 2017 --> Jun 2017
- | ZB-168 / Zura Bio
Trial completion date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 21, 2014
P1, N=60, Not yet recruiting, Sponsor: Pfizer
Trial primary completion date: May 2017 --> Jun 2017 Trial completion date: May 2017 --> Jun 2017
- || ZB-168 / Zura Bio
Trial initiation date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 21, 2014
P1, N=60, Not yet recruiting, Sponsor: Pfizer
Trial completion date: May 2017 --> Jun 2017 Initiation date: Mar 2014 --> May 2014
- Cosentyx (secukinumab) / Novartis
Trial primary completion date: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - May 20, 2014
P2, N=39, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2014 --> May 2014 Trial primary completion date: Jul 2014 --> May 2014
- Cosentyx (secukinumab) / Novartis
Trial completion date: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - May 20, 2014
P2, N=39, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2014 --> May 2014 Trial completion date: Jul 2014 --> May 2014
- | Cosentyx (secukinumab) / Novartis
Enrollment closed: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - May 20, 2014
P2, N=39, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2014 --> May 2014 Recruiting --> Active, not recruiting
- ||||| Enrollment closed: INFORMS: FTY720 in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - May 20, 2014
P3, N=969, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| dimethyl fumarate / Generic mfg.
Trial completion: MANAGE: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (clinicaltrials.gov) - May 20, 2014
P4, N=237, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || dimethyl fumarate / Generic mfg.
Trial primary completion date: MANAGE: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (clinicaltrials.gov) - May 20, 2014
P4, N=230, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Trial primary completion date: Oct 2013 --> Oct 2013
- ||| Tysabri (natalizumab) / Biogen, Royalty
Clinical data, Real-world evidence, Real-world: Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (clinicaltrials.gov) - May 18, 2014
P=N/A, N=700, Not yet recruiting, Sponsor: Biogen Idec
- | Tysabri (natalizumab) / Biogen, Royalty
Trial initiation date: A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State (clinicaltrials.gov) - May 18, 2014
P4, N=20, Completed, Sponsor: Biogen Idec
Trial primary completion date: Oct 2013 --> Oct 2013 Initiation date: Sep 2008 --> Nov 2008
- Clinical: IMMUNOSEP: Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (clinicaltrials.gov) - May 18, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: University Hospital, Bordeaux